Daxxify vs. Botox: What a Split-Face Clinical Trial Actually Showed

Botox® (onabotulinumtoxinA) and Daxxify™ (daxibotulinumtoxinA-lanm) both relax the muscles that cause wrinkles, but they're built differently: Daxxify uses a peptide-based formula that tends to last longer (often 6+ months vs. Botox's typical 3-4), while Botox has two more decades of track record and broader FDA-approved uses. In Aluma's own split-face clinical trial, patients received Botox on one side of the face and Daxxify on the other, Daxxify held up noticeably longer in the forehead area (glabella), and most patients preferred it by month three. Neither is universally "better"; the right choice depends on how long you want results to last and how your face responds to each formula, which is exactly why we ran the trial below instead of just repeating manufacturer claims

Natural-Looking Results (Injector Framing)

For many patients, “natural” means softening movement without freezing expression. In our experience, Daxxify can deliver a smooth, soft appearance when:

• you dose to indication rather than unit-converting from other toxins,
• you map injection points to actual dynamic lines (not just habit), and
• you pair it with patient education on the settle window (1 - 2 weeks) and maintenance cadence.

Position this clearly in consults: Daxxify aims to enhance skin’s visual quality and refine expression lines while maintaining a patient’s natural look - especially valuable for patients on camera, in sales, or those who’ve been “over-treated” elsewhere.

Choosing Daxxify: Considerations for Consult & Candidacy

As with any neuromodulator, assess:

• Goals & lifestyle: event timelines, desired visit frequency, tolerance for gradual onset vs. rapid polish.
• Dynamic pattern & muscle strength: tailor dose and spread to forehead, glabella, and canthus behavior.
• History: prior toxin response, duration, and any variability in effect over time.
• Adjacencies: whether they’ll benefit from a movement + shape + skin plan (e.g., tox + filler + a skin-quality tool such as Skinvive, plus skincare/SPF).

Set expectations up front: onset can be felt quickly for some, but the best readout is usually at 1 - 2 weeks; durability depends on individual biology and treatment area.

Botox vs Daxxify: Our 4-Month Split-Face Series (Educational)

Design (December 2022 start): Led by Dr. Michael Lafkas, we ran a small, internal, split-face case series (n=7) comparing Daxxify to Botox over four months. This was an educational demonstration, not a randomized controlled trial. We captured procedure and progress videos at multiple time points.

What we saw (high-level):

• 3-Month Signal: By month three, the Daxxify side was visibly smoother in most participants, while movement had already started returning on the Botox side.
• Region Differences: Daxxify stood out in the glabella (we observed ~50 - 80% longer-lasting softening vs. Botox in this area) and performed well around the lateral canthus; forehead outcomes were closer to parity.
• Participant Preference: Most preferred the Daxxify side aesthetically by Month 3.
• Ethics/Comfort: To avoid prolonged asymmetry, we re-treated the Botox side at ~3 months and concluded the series at Month 4.

That last point matters if you're comparing cost: a fair cost comparison isn't "price per unit," it's price per month of results, because Botox needs touch-ups sooner. More on that below:

A professional’s perspective: In 18 years of practice, Dr. Lafkas has observed that some patients perceive diminishing benefit from their historical toxin choice. For those patients, Daxxify offers a credible alternative - and enthusiasm has been high.

For a deeper dive into the comparative efficacy and safety of Daxxify versus Botox, you can read Dr. Lafkas’ peer-reviewed study published in Aesthetic Surgery Journal Open Forum. It provides a thorough analysis grounded in clinical data and offers valuable insights for patients considering both options. Read the full paper here.

How to Position Each in Your Menu

• Botox®: Gold-standard familiarity, robust data history, wide patient awareness, flexible dosing strategies.
• Daxxify™: Strong fit for patients who prioritize longer intervals and quick polish - use consult scripts that emphasize natural expression and a predictable settle window.

Program idea: Build two clear pathways on your service menu:

• Classic Maintenance: 3–4 neuromodulator visits/year (Botox).
• Extended Maintenance: ~2 neuromodulator visits/year (Daxxify), personalized to response.
  Bundle either pathway with skin-quality and skincare touchpoints for holistic results.

FAQs

Which lasts longer in practice?
In our small split-face series, Daxxify maintained effect longer - especially in the glabella - while forehead differences were smaller. Individual biology, area, and dose matter. Your patients’ mileage will vary.

How fast is the onset?
Some patients feel/see change within a couple of days; set expectations that best read is at 1 - 2 weeks for either product.

Can I convert units 1:1?
No. Units are not interchangeable across neuromodulators. Dose to the label, your training, and the clinical presentation.

Is the result “frozen”?
Not when mapped and dosed correctly. With appropriate planning, both products can soften movement while preserving expression; many injectors report particularly soft, natural finishes with Daxxify.

From the Aluma Team

Aluma helps injectors operationalize new modalities - protocols, pricing strategy, consent language, photo standards, and compliant content that educates without over-promising. If you’re an injector (especially in Southern California) looking for a high-standard, growth-minded network, explore opportunities at Aluma to learn more and apply.

For licensed medical professionals. Educational content only; not medical advice. Always follow product labeling, training, and your clinical judgment.